Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

被引：0
|
作者：
Garmezy, Benjamin
Zhang, Tian
Laccetti, Andrew Leonard
Economides, Minas P.
Shah, Amishi Yogesh
Tannir, Nizar M.
Jonasch, Eric
Msaouel, Pavlos
Zurita, Amado J.
Corn, Paul Gettys
Venkatesan, Aradhana M.
Brown, Landon Carter
Kao, Chester
Kinsey, Emily Noelle
Harrison, Michael Roger
Armstrong, Andrew J.
George, Daniel J.
Campbell, Matthew T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Duke Canc Inst, Durham, NC USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17090
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study
    Jammal, Nadya
    Pan, Eva
    Hurwitz, Michael
    Abramovitz, Rebecca B.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 556 - 563
  • [2] Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.
    Hess, G. P.
    Chen, C.
    Liu, Z.
    Gesme, D. H.
    Agarwala, S. S.
    Hill, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy
    Takagi, Toshio
    Yoshida, Kazuhiko
    Kondo, Tsunenori
    Fukuda, Hironori
    Ishihara, Hiroki
    Kobayashi, Hirohito
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1744 - 1750
  • [4] Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
    Wu, Jialu
    Huang, Hui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3977 - 3982
  • [5] USE OF TYROSINE KINASE INHIBITORS (TKI) IN HAEMODIALYTIC METASTATIC RENAL CELL CARCINOMA PATIENTS
    Sabbatini, R.
    Porta, C.
    Procopio, G.
    Ferrari, A.
    Conte, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
  • [6] Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma
    Lightowlers, S. V.
    Greef, B.
    Eisen, T.
    Matakidou, A.
    Fife, K.
    Cameron, E. A.
    ANNALS OF ONCOLOGY, 2019, 30 (01) : 150 - 151
  • [7] Impact of tyrosine kinase inhibitors and cytoreductive nephrectomy in patients with metastatic renal cell carcinoma
    Kassouf, Wassim
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2009, 3 (04): : 292 - 292
  • [8] Cardiotoxicity of tyrosine kinase inhibitors among veterans diagnosed with renal cell carcinoma.
    Lynch, Kristine E.
    Lynch, Julie Ann
    Efimova, Olga
    Chang, Jiwon
    Berse, Brygida
    Rivera, Donna
    Becker, Daniel Jacob
    DuVall, Scott L.
    Filipski, Kelly Kristin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Skeletal muscle density as a positive predictive factor for nivolumab therapy in patients with metastatic renal cell carcinoma.
    Ekenel, Meltem
    Sari, Murat
    Aliyev, Samil
    Basaran, Mert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] SAFETY AND TOLERABILITY OF TYROSINE KINASE INHIBITORS (TKI) IN HEMODIALYTIC METASTATIC RENAL CELL CARCINOMA PATIENTS
    Sabbatini, Roberto
    Porta, Camillo
    Procopio, Giuseppe
    Gasparro, Donatello
    Ferrari, Alessia
    Pagano, Maria
    Conte, Pier Franco
    ANNALS OF ONCOLOGY, 2009, 20
12345